...executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield... ...of autism spectrum disorder, Type I diabetes and, via subsidiary Axovia Therapeutics Inc., Bardet-Biedl syndrome. Deerfield... ...MET and RAS pathway inhibitor the company believes could overcome resistance to approved MET inhibitors.
Jeff Cranmer
AveXis
Deerfield
Apollomics
Sarepta...
...of T. Rowe Price, Wellington Management, Avoro Capital Advisors, Vivo Capital and other, undisclosed investors.Northpond, Deerfield... ...company Encodia raised a $75 million series C round, with lead investors Northpond Ventures and Deerfield...
...Emerging Company Profile: Out of stealth, Deerfield-backed Nuvalent prepares for clinic By Paul Bonanos, Associate Editor... ...in stealth mode during which it subsisted on a $50 million series A round from Deerfield... ...two targeted programs for non-small cell lung cancer.Nuvalent Inc.’s emergence represents the latest evidence of Deerfield...
...executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield... ...of autism spectrum disorder, Type I diabetes and, via subsidiary Axovia Therapeutics Inc., Bardet-Biedl syndrome. Deerfield... ...MET and RAS pathway inhibitor the company believes could overcome resistance to approved MET inhibitors.
Jeff Cranmer
AveXis
Deerfield
Apollomics
Sarepta...
...of T. Rowe Price, Wellington Management, Avoro Capital Advisors, Vivo Capital and other, undisclosed investors.Northpond, Deerfield... ...company Encodia raised a $75 million series C round, with lead investors Northpond Ventures and Deerfield...
...Emerging Company Profile: Out of stealth, Deerfield-backed Nuvalent prepares for clinic By Paul Bonanos, Associate Editor... ...in stealth mode during which it subsisted on a $50 million series A round from Deerfield... ...two targeted programs for non-small cell lung cancer.Nuvalent Inc.’s emergence represents the latest evidence of Deerfield...